Monash IVF Group Ltd (ASX: MVF) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Monash IVF Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $247.42 million
P/E Ratio 18.68
Dividend Yield 3.66%
Shares Outstanding 389.63 million
Earnings per share 0.038
Dividend per share 0.04
Year To Date Return -11.29%
Earnings Yield 5.35%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Monash IVF Group Ltd (ASX: MVF)
Latest News

a woman
Share Fallers

Monash IVF Group Ltd (ASX:MVF) shares plunge 10% on sizeable drop in profits

The Monash IVF Group Ltd (ASX:MVF) share price has plunged 10% after releasing a disappointing full year result. Should you…

Read more »

a woman
Share Market News

Earnings season week five preview

Results are due from Bellamy's Australia Ltd (ASX:BAL), NEXTDC Ltd (ASX:NXT), and Ramsay Health Care Limited (ASX:RHC) this week...

Read more »

a woman
Share Market News

5 things to watch on the ASX on Monday

The shares of BHP Billiton Limited (ASX:BHP), G8 Education Ltd (ASX:GEM), and Monash IVF Group Ltd (ASX:MVF) will be on…

Read more »

a woman
Cheap Shares

Should you buy these unloved ASX shares?

Should you buy Telstra Corporation Ltd (ASX:TLS) shares yet?

Read more »

a woman
⏸️ Investing

3 healthcare shares for a healthy portfolio

These 3 healthcare shares could be long-term opportunities.

Read more »

a woman
⏸️ Investing

3 ASX shares that could see earnings slide next year

It isn't just Telstra Corporation Ltd (ASX:TLS) facing an earnings gap. These three shares could also see their earnings slide…

Read more »

a woman
⏸️ Investing

Why growing cities are accelerating returns for investors

Growing cities are accelerating growth.

Read more »

a woman
⏸️ Investing

Buy this blue-chip stock for the surge in M&A to a more than 10-year high

Investors looking to benefit from the expected boom in takeover activity on our market shouldn't try to pick the next…

Read more »

a woman
⏸️ Investing

Should you buy these high-yield dividend shares?

Should you grab hold of the National Australia Bank Ltd (ASX:NAB) dividend and two others?

Read more »

a woman
⏸️ Investing

These 3 ASX shares just fell to 52-week lows

The iSelect Ltd (ASX:ISU) share price is one of three falling to 52-week lows today. Here's why...

Read more »

a woman
⏸️ Investing

These 3 ASX shares just fell to 52-week lows

he G8 Education Ltd (ASX:GEM) share price is one of three that fell to a 52-week low on Thursday. Is…

Read more »

a woman
⏸️ Investing

Why these 4 ASX shares are sinking lower today

The Orocobre Limited (ASX:ORE) share price is one of four sinking lower on Tuesday. Here's what you need to know...

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
04 Mar 2026 $0.0120 100.00% Interim 10 Apr 2026
06 Mar 2025 $0.0260 100.00% Interim 11 Apr 2025
05 Sep 2024 $0.0250 100.00% Final 11 Oct 2024
07 Mar 2024 $0.0250 100.00% Interim 05 Apr 2024
07 Sep 2023 $0.0220 100.00% Final 11 Oct 2023
08 Mar 2023 $0.0220 100.00% Interim 06 Apr 2023
08 Sep 2022 $0.0220 100.00% Final 07 Oct 2022
07 Mar 2022 $0.0220 100.00% Interim 04 Apr 2022
09 Sep 2021 $0.0210 100.00% Final 08 Oct 2021
09 Mar 2021 $0.0210 100.00% Interim 07 Apr 2021
05 Mar 2020 $0.0210 100.00% Interim 02 Oct 2020
05 Sep 2019 $0.0300 100.00% Final 11 Oct 2019
06 Sep 2018 $0.0260 100.00% Final 12 Oct 2018
08 Mar 2018 $0.0340 100.00% Interim 06 Apr 2018
06 Sep 2017 $0.0000 100.00% Final 13 Oct 2017
02 Mar 2017 $0.0430 100.00% Interim 07 Apr 2017
06 Sep 2016 $0.0450 100.00% Final 14 Oct 2016
08 Mar 2016 $0.0400 100.00% Interim 08 Apr 2016

MVF ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Monash IVF Group Ltd

Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, whichoffer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.

MVF Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
19 Mar 2026 $0.64 $-0.01 -1.56% 537,442 $0.64 $0.64 $0.63
18 Mar 2026 $0.64 $0.00 0.00% 130,331 $0.64 $0.65 $0.64
17 Mar 2026 $0.64 $0.01 1.59% 267,266 $0.64 $0.65 $0.64
16 Mar 2026 $0.63 $0.00 0.00% 248,679 $0.63 $0.64 $0.63
13 Mar 2026 $0.63 $-0.01 -1.57% 159,452 $0.63 $0.65 $0.63
12 Mar 2026 $0.64 $-0.01 -1.56% 1,099,666 $0.65 $0.65 $0.63
11 Mar 2026 $0.64 $-0.01 -1.55% 436,320 $0.65 $0.65 $0.63
10 Mar 2026 $0.65 $0.01 1.56% 866,077 $0.65 $0.66 $0.64
09 Mar 2026 $0.64 $-0.02 -3.03% 1,795,995 $0.66 $0.66 $0.63
06 Mar 2026 $0.66 $-0.01 -1.50% 503,438 $0.67 $0.67 $0.65
05 Mar 2026 $0.67 $0.02 3.08% 558,234 $0.65 $0.67 $0.65
04 Mar 2026 $0.65 $-0.03 -4.44% 766,510 $0.67 $0.67 $0.64
03 Mar 2026 $0.68 $-0.01 -1.46% 357,354 $0.68 $0.70 $0.67
02 Mar 2026 $0.69 $-0.01 -1.44% 349,436 $0.69 $0.70 $0.68
27 Feb 2026 $0.70 $-0.02 -2.82% 489,779 $0.71 $0.71 $0.68
26 Feb 2026 $0.71 $0.02 2.90% 3,418,608 $0.68 $0.72 $0.64
25 Feb 2026 $0.69 $-0.01 -1.43% 917,382 $0.70 $0.71 $0.69
24 Feb 2026 $0.70 $-0.03 -4.11% 1,769,525 $0.73 $0.73 $0.70
23 Feb 2026 $0.73 $0.01 1.38% 548,439 $0.73 $0.74 $0.73
20 Feb 2026 $0.73 $0.01 1.39% 256,390 $0.73 $0.73 $0.72
19 Feb 2026 $0.72 $0.01 1.41% 348,555 $0.72 $0.73 $0.72
18 Feb 2026 $0.71 $0.00 0.00% 198,486 $0.72 $0.72 $0.71
17 Feb 2026 $0.71 $0.01 1.42% 266,478 $0.70 $0.72 $0.70

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
29 Dec 2025 Catherine (Cathy) Aston Sell 75,000 $53,928
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Zita Peach Non-Executive Director Oct 2016
Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for industry players such as CSL Limited, Fresenius Kabi and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. She is a Non-executive Director of three private equity owned companies, Icon Group Pty Ltd, Vet Partners Pty Ltd and Nucleus Network Pty Ltd.
Mr Richard Hugh Davis Non-Executive ChairmanNon-Executive Director Jun 2014
Mr Davis worked for InvoCare for 20 years until 2008. For most of that time, he held the position of CEO and managed the growth of that business through several ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is member of Risk Committee.
Dr Dwayne Crombie Non-Executive Director Nov 2025
Mr Crombie has spent his entire career working in various parts of the healthcare system in both New Zealand and Australia. His experience has spanned public hospital provision, community-based, mental health and disability services. It has also included funding of public health and disability services, aged care, private health insurance and private healthcare. Dwayne originally trained in medicine and specialised in public health before moving on to senior management roles. He worked for global healthcare organisation Bupa for more than 15 years in several Managing Director roles. Dwaynes current governance roles include Southern Cross Healthcare and Southern Cross Society, as well as being chair of Repromed New Zealand, an IVF Provider.
Mr Neil John Broekhuizen Non-Executive Director Jun 2014
Mr Broekhuizen is the Joint Chief Executive Officer of Ironbridge. He has over 35 years of experience in the finance industry including 29 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. He is member of Risk Committee.
Dr Richard Charles Henshaw Executive Director Apr 2014
Dr Henshaw has practiced in the field of reproductive medicine since 1995. He worked as a Fertility Specialist for the Group and retired from clinical practice in August 2025. He has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
Ms Catherine Jane West Non-Executive Director Sep 2020
Ms West has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe.
Ms Catherine (Cathy) Ann Aston Non-Executive Director Feb 2024
Ms Aston is a Non executive Director/Chair of listed and unlisted entities covering technology, financial services, marketing services, health and government sectors across Australia and Asia. She has commercial background with executive roles in finance, marketing and strategy, including as CFO for Telstra International and Chief Executive Officer of a mobiles joint venture in Sri Lanka. She is currently a Non-executive Director of Macquarie Investment Management Ltd (Chair of the Audit, Risk and Compliance committee), IVE Group Ltd (Chair of the Audit and Risk Committee) and IMB Bank Ltd (Chair). She is Chair of Risk Committee.
Ms Victoria Atkinson Non-Executive Director Jan 2026
--
Ms Rebecca Dean Company SecretaryGeneral Counsel Mar 2026
-
Johannes Lagerwij Asia Managing Director
-
Peggy North Chief Corporate Shared Services Officer
-
Tedd Fuell Chief Governance and Risk Officer
-
Thierry Panthier Chief Information Officer
-
Rebecca Redden Chief Operating Officer
-
Deirdre Zander Fox Chief Scientific Officer
-
Rebecca Dean Company SecretaryGeneral Counsel
-
Luk Rombauts Group Medical Director
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Washington H Soul Pattinson And Company Limited 37,767,969 9.69%
Argo Investments Limited 28,381,705 7.28%
Citicorp Nominees Pty Limited 27,642,111 7.09%
J P Morgan Nominees Australia Pty Limited 27,637,494 7.09%
HSBC Custody Nominees (Australia) Limited 21,532,960 5.53%
HSBC Custody Nominees (Australia) Limited A/C 2 9,141,392 2.35%
UBS Nominees Pty Ltd 4,642,413 1.19%
BNP Paribas Nominees Pty Ltd 4,123,674 1.06%
Masfen Securities Limited 4,000,000 1.03%
J & P Chick Pty Limited 3,930,000 1.01%
Creabird Pty Ltd 2,650,000 0.68%
Neweconomy Com Au Nominees Pty Limited 2,637,466 0.68%
BNP Paribas Nominees Pty Ltd i 2,584,913 0.66%
Mr Troy Benjamin Ince & Mrs Nadine Julie Miller 2,250,000 0.58%
Ippoliti Pty Ltd 2,011,336 0.52%
Pacific Custodians Pty Limited 2,007,027 0.52%
Netwealth Investments Limited 1,705,141 0.44%
Mr Prashant Nadkarni 1,461,484 0.38%
Gregg Property Holdings Pty Ltd 1,317,300 0.34%
Mclachlan Future Fund Pty Ltd 1,300,000 0.32%

Profile

since

Note